Evidence map›Paper›PMID 39370432›Full record

ArticleCell death & disease2024

In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo.

Federica Colombo, Virginia Guzzeloni, Cise Kizilirmak, Francesca Brambilla, Jose Manuel Garcia-Manteiga, Anna Sofia Tascini, Federica Moalli, Francesca Mercalli, Maurilio Ponzoni, Rosanna Mezzapelle and 7 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. SSTNSignal transduction and targeted therapy · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Federica Colombo *Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Virginia Guzzeloni *Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Cise KizilirmakDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesca BrambillaDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Jose Manuel Garcia-ManteigaCenter for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-5481-040X
Anna Sofia TasciniUniversita' Vita-Salute San Raffaele, Milan, Italy.
Federica MoalliDivision of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesca MercalliHospital "Maggiore della Carità", Unit of Pathology, Novara, Italy.
Maurilio PonzoniUniversita' Vita-Salute San Raffaele, Milan, Italy.
Rosanna MezzapelleDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-1271-8998
Marina FerrariniB-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Elisabetta FerreroB-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Roberta VisoneDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Marco RasponiDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.ORCID 0000-0002-2904-8652
Marco E BianchiDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-5329-6445
Samuel ZambranoDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. zambrano.samuel@hsr.it.ORCID 0000-0002-9384-2017
Alessandra AgrestiDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. agresti.alessandra@hsr.it.ORCID 0000-0001-5006-9506

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) [IG-18623Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFAG [ID-27415]Fondazione Cariplo (Cariplo Foundation) 2018-0551
6 · The paper itself

Abstract

Multiple myeloma (MM) is linked to chronic NF-κB activity in myeloma cells, but this activity is generally considered a cell-autonomous property of the cancer cells. The precise extent of NF-κB activation and the contributions of the physical microenvironment and of cell-to-cell communications remain largely unknown. By quantitative immunofluorescence, we found that NF-κB is mildly and heterogeneously activated in a fraction of MM cells in human BMs, while only a minority of MM cells shows a strong activation. To gain quantitative insights on NF-κB activation in living MM cells, we combined advanced live imaging of endogenous p65 Venus-knocked-in in MM.1S and HS-5 cell lines to model MM and mesenchymal stromal cells (MSCs), cell co-cultures, microfluidics and custom microbioreactors to mimic the 3D-interactions within the bone marrow (BM) microenvironment. We found that i) reciprocal MM-MSC paracrine crosstalk and cell-to-scaffold interactions shape the inflammatory response in the BM; ii) the pro-inflammatory cytokine IL-1β, abundant in MM patients' plasma, activates MSCs, whose paracrine signals are responsible for strong NF-κB activation in a minority of MM cells; iii) IL-1β, but not TNF-α, activates NF-κB in vivo in BM-engrafted MM cells, while its receptor inhibitor Anakinra reduces the global NF-κB activation. We propose that NF-κB activation in the BM of MM patients is mild, restricted to a minority of cells and modulated by the interplay of restraining physical microenvironmental cues and activating IL-1β-dependent stroma-to-MM crosstalk.

Indexed as

Coculture TechniquesMesenchymal Stem CellsMultiple MyelomaNF-kappa BCell CommunicationCell Line, TumorHumansInterleukin-1betaParacrine CommunicationSignal TransductionStromal CellsTranscription Factor RelATumor MicroenvironmentInterleukin-1betaNF-kappa BTranscription Factor RelA

Identifiers

PMID39370432
PMCPMC11456592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.